A bivalent vaccine based on a replication-incompetent influenza virus protects against Streptococcus pneumoniae and influenza virus infection

Journal of Virology

Volumn 88, Issue 22, 2014, Pages 13410-13417

  Katsura, Hiroaki ^a   Piao, Zhenyu ^b   Iwatsuki Horimoto, Kiyoko ^a   Akeda, Yukihiro ^b   Watanabe, Shinji ^c,d   Horimoto, Taisuke ^e   Oishi, Kazunori ^b,f   Kawaoka, Yoshihiro ^a,c,g  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d UNIVERSITY OF MIYAZAKI   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

^f NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; PNEUMOCOCCAL SURFACE PROTEIN A; UNCLASSIFIED DRUG; VIRUS VACCINE; INFLUENZA VACCINE; RECOMBINANT VACCINE; STREPTOCOCCUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL COLONIZATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HA KO PSPA VIRUS; HEMAGGLUTININ KNOCKOUT INFLUENZA VIRUS; IMMUNOFLUORESCENCE TEST; IMMUNOGENICITY; INFLUENZA; LUNG LAVAGE; MOUSE; NASOPHARYNX; NONHUMAN; PROTEIN EXPRESSION; STREPTOCOCCUS PNEUMONIA; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; ANIMAL; DISEASE MODEL; GENE INACTIVATION; GENETICS; HETEROZYGOTE; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS; MICROBIOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; PREVENTION AND CONTROL; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS;

ANIMALS; BACTERIAL PROTEINS; CARRIER STATE; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCKOUT TECHNIQUES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; NASOPHARYNX; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; SURVIVAL ANALYSIS; VACCINES, SYNTHETIC;

EID: 84908368445     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01205-14     Document Type: Article

References (42)

1. Bogaert D, De Groot R, Hermans PW. 2004. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 4:144-154. http://dx.doi.org/10.1016/S1473-3099(04)00938-7.
2. Jambo KC, Sepako E, Heyderman RS, Gordon SB. 2010. Potential role for mucosally active vaccines against pneumococcal pneumonia. Trends Microbiol. 18:81-89. http://dx.doi.org/10.1016/j.tim.2009.12.001.
3. Kadioglu A, Weiser JN, Paton JC, Andrew PW. 2008. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat. Rev. Microbiol. 6:288-301. http://dx.doi.org/10.1038/nrmicro1871.
4. McCullers JA. 2006. Insights into the interaction between influenza virus and pneumococcus. Clin. Microbiol. Rev. 19:571-582. http://dx.doi.org/10.1128/CMR.00058-05.
5. Dagan R, Givon-Lavi N, Zamir O, Fraser D. 2003. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr. Infect. Dis. J. 22:532-540. http://dx.doi.org/10.1097/00006454-200306000-00009.
6. Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, Mendelman PM, Bohidar N, Yagupsky P. 1996. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J. Infect. Dis. 174:1271-1278. http://dx.doi.org/10.1093/infdis/174.6.1271.
7. American Academy of Pediatrics Committee on Infectious Diseases. 2000. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics 106:362-366. http://dx.doi.org/10.1542/peds.106.2.362.
8. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A, Network ABCSotEIP. 2003. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348:1737-1746. http://dx.doi.org/10.1056/NEJMoa022823.
9. Moffitt KL, Malley R. 2011. Next generation pneumococcal vaccines. Curr. Opin. Immunol. 23:407-413. http://dx.doi.org/10.1016/j.coi.2011.04.002.
10. Rodgers GL, Klugman KP. 2011. The future of pneumococcal disease prevention. Vaccine 29(Suppl 3):C43-C48. http://dx.doi.org/10.1016/j.vaccine.2011.07.047.
11. Jedrzejas MJ. 2007. Unveiling molecular mechanisms of bacterial surface proteins: Streptococcus pneumoniae as a model organism for structural studies. Cell Mol. Life Sci. 64:2799-2822. http://dx.doi.org/10.1007/s00018-007-7125-8.
12. Ochs MM, Bartlett W, Briles DE, Hicks B, Jurkuvenas A, Lau P, Ren B, Millar A. 2008. Vaccine-induced human antibodies to PspA augment complement C3 deposition on Streptococcus pneumoniae. Microb. Pathog. 44:204-214. http://dx.doi.org/10.1016/j.micpath.2007.09.007.
13. Ren B, Szalai AJ, Hollingshead SK, Briles DE. 2004. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect. Immun. 72:114-122. http://dx.doi.org/10.1128/IAI.72.1.114-122.2004.
14. Nabors GS, Braun PA, Herrmann DJ, Heise ML, Pyle DJ, Gravenstein S, Schilling M, Ferguson LM, Hollingshead SK, Briles DE, Becker RS. 2000. Immunization of healthy adults with a single recombinant pneumococcal surface protein A (PspA) variant stimulates broadly cross-reactive antibodies to heterologous PspA molecules. Vaccine 18:1743-1754. http://dx.doi.org/10.1016/S0264-410X(99)00530-7.
15. Ezoe H, Akeda Y, Piao Z, Aoshi T, Koyama S, Tanimoto T, Ishii KJ, Oishi K. 2011. Intranasal vaccination with pneumococcal surface protein A plus poly(I:C) protects against secondary pneumococcal pneumonia in mice. Vaccine 29:1754-1761. http://dx.doi.org/10.1016/j.vaccine.2010.12.117.
16. Ambrose CS, Luke C, Coelingh K. 2008. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respir. Viruses 2:193-202. http://dx.doi.org/10.1111/j.1750-2659.2008.00056.x.
17. Cox RJ, Brokstad KA, Ogra P. 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59:1-15. http://dx.doi.org/10.1111/j.0300-9475.2004.01382.x.
18. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ, Centers for Disease Control and Prevention (CDC). 2010. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.MMWRRecomm. Rep. 59(RR-8): 1-62.
19. Katsura H, Iwatsuki-Horimoto K, Fukuyama S, Watanabe S, Sakabe S, Hatta Y, Murakami S, Shimojima M, Horimoto T, Kawaoka Y. 2012. A replication-incompetent virus possessing an uncleavable hemagglutinin as an influenza vaccine. Vaccine 30:6027-6033. http://dx.doi.org/10.1016/j.vaccine.2012.07.059.
20. Baker SF, Guo H, Albrecht RA, García-Sastre A, Topham DJ, Martínez-Sobrido L. 2013. Protection against lethal influenza with a viral mimic. J. Virol. 87:8591-8605. http://dx.doi.org/10.1128/JVI.01081-13.
21. Powell TJ, Silk JD, Sharps J, Fodor E, Townsend AR. 2012. Pseudotyped influenza A virus as a vaccine for the induction of heterotypic immunity. J. Virol. 86:13397-13406. http://dx.doi.org/10.1128/JVI.01820-12.
22. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. 1999. Generation of influenza A viruses entirely from cloned cDNAs. Proc. Natl. Acad. Sci. U. S. A. 96:9345-9350. http://dx.doi.org/10.1073/pnas.96.16.9345.
23. Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, van Ginkel FW, Jr, Benjamin WH. 2003. Immunization with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J. Infect. Dis. 188:339-348. http://dx.doi.org/10.1086/376571.
24. Briles DE, Novak L, Hotomi M, van Finkel FW, King J. 2005. Nasal colonization with Streptococcus pneumoniae includes subpopulations of surfaces and invasive pneumococci. Infect. Immun. 73:6945-6951. http://dx.doi.org/10.1128/IAI.73.10.6945-6951.2005.
25. Watanabe T, Watanabe S, Noda T, Fujii Y, Kawaoka Y. 2003. Exploitation of nucleic acid packaging signals to generate a novel influenza virusbased vector stably expressing two foreign genes. J. Virol. 77:10575-10583. http://dx.doi.org/10.1128/JVI.77.19.10575-10583.2003.
26. Kida H, Brown LE, Webster RG. 1982. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122:38-47. http://dx.doi.org/10.1016/0042-6822(82)90375-0.
27. Martin K, Helenius A. 1991. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 67:117-130. http://dx.doi.org/10.1016/0092-8674(91) 90576-K.
28. Ferreira DM, Darrieux M, Oliveira ML, Leite LC, Miyaji EN. 2008. Optimized immune response elicited by a DNA vaccine expressing pneumococcal surface protein A is characterized by a balanced immunoglobulin G1 (IgG1)/IgG2a ratio and proinflammatory cytokine production. Clin. Vaccine Immunol. 15:499-505. http://dx.doi.org/10.1128/CVI.00400-07.
29. Morens DM, Taubenberger JK, Fauci AS. 2008. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J. Infect. Dis. 198:962-970. http://dx.doi.org/10.1086/591708.
30. Gill JR, Sheng ZM, Ely SF, Guinee DG, Beasley MB, Suh J, Deshpande C, Mollura DJ, Morens DM, Bray M, Travis WD, Taubenberger JK. 2010. Pulmonary pathologic findings of fatal 2009 pandemic influenza A/H1N1 viral infections. Arch. Pathol. Lab. Med. 134:235-243.
31. Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V, Hui J, Tokarz R, Briese T, Baumeister E, Lipkin WI. 2009. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 4:e8540. http://dx.doi.org/10.1371/journal.pone.0008540.
32. Chaussee MS, Sandbulte HR, Schuneman MJ, Depaula FP, Addengast LA, Schlenker EH, Huber VC. 2011. Inactivated and live, attenuated influenza vaccines protect mice against influenza: Streptococcus pyogenes super-infections. Vaccine 29:3773-3781. http://dx.doi.org/10.1016/j.vaccine.2011.03.031.
33. Huber VC, Peltola V, Iverson AR, McCullers JA. 2010. Contribution of vaccine-induced immunity toward either theHAor theNAcomponent of influenza viruses limits secondary bacterial complications. J. Virol. 84: 4105-4108. http://dx.doi.org/10.1128/JVI.02621-09.
34. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. 2008. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J. Immunol. 181:4168-4176. http://dx.doi.org/10.4049/jimmunol.181.6.4168.
35. LaMere MW, Lam HT, Moquin A, Haynes L, Lund EF, Randall TD, Kaminski DA. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186:4331-4339. http://dx.doi.org/10.4049/jimmunol.1003057.
36. Rimmelzwaan GF, Fouchier RA, Osterhaus AD. 2007. Influenza virusspecific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18:529-536. http://dx.doi.org/10.1016/j.copbio.2007.11.002.
37. Oma K, Zhao J, Ezoe H, Akeda Y, Koyama S, Ishii KJ, Kataoka K, Oishi K. 2009. Intranasal immunization with a mixture of PspA and a Toll-like receptor agonist induces specific antibodies and enhances bacterial clearance in the airways of mice. Vaccine 27:3181-3188. http://dx.doi.org/10.1016/j.vaccine.2009.03.055.
38. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa V. 2004. Innate antiviral responses by means of TLR7-mediated recognition of singlestranded RNA. Science 303:1529-1531. http://dx.doi.org/10.1126/science.1093616.
39. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S, Hartmann G. 2006. 5-Triphosphate RNA is the ligand for RIG-I. Science 314:994-997. http://dx.doi.org/10.1126/science.1132505.
40. Pichlmair A, Schulz O, Tan CP, Näslund TI, Liljeström P, Weber F, Reis e Sousa C. 2006. RIG-I-mediated antiviral responses to singlestranded RNA bearing 5'-phosphates. Science 314:997-1001. http://dx.doi.org/10.1126/science.1132998.
41. Blander JM, Medzhitov R. 2006. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 440:808-812. http://dx.doi.org/10.1038/nature04596.
42. Schulz O, Diebold SS, Chen M, Nälund TI, Nolte MA, Alexopoulou L, Azuma YT, Flavell RA, Liljeströ P, Reis e Sousa C. 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892. http://dx.doi.org/10.1038/nature03326.